Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RT-PEPC in Relapsed Mantle Cell Lymphoma
NCT00151281Phase 2Completed
- Sponsor
- Weill Cornell Medicine
- Start
- Nov 2004
- Primary completion
- Dec 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of thalidomide in mantle cell lymphoma (MCL), sponsored by Weill Cornell Medicine. Primary endpoints: Overall Response Rate at 38 months, Time to Progression at 38 months and 2 more. Started Nov 2004; status: completed.
02
Drugs
thalidomide
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT00151281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00151281.